Melilla

Researchers are evaluating the effectiveness and safety of subcutaneous immunotherapy for patients aged 12 to 65 years who have allergic rhinitis or rhinoconjunctivitis, with or without mild to moderate asthma, caused by sensitization to house dust mites Dermatophagoides pteronyssinus and/or Dermatophagoides farinae. This is a double-blinded, placebo-controlled, multicenter Phase 3 trial involving 150 participants to determine the treatment's impact over one year. Participants are randomly assigned to one of three groups: two active treatment groups receiving purified allergenic extracts with concentrations of either 10,000 UT/mL or 30,000 UT/mL, and one placebo group receiving a similar solution without active ingredients. All treatments are given via subcutaneous injections as part of a one-year medication regimen. Throughout the study, participants will use a smartphone to record symptoms and medication use. Researchers will monitor combined symptoms and medication scores over 12 months. Participants will be regularly assessed for safety, treatment adherence, and allergic reactions. The study aims to measure improvements in allergic symptoms and medication needs while ensuring safety during the treatment period.